Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis
- First Online:
- Cite this article as:
- Zhou, P., Du, LF., Lv, GQ. et al. Breast Cancer Res Treat (2011) 127: 813. doi:10.1007/s10549-010-1294-0
- 256 Downloads
The matrix metalloproteinases (MMP) can degrade various components of the extracellular matrix and its functional genetic polymorphisms may be associated with breast cancer risk. However, this relationship remains controversial. A meta-analysis was conducted in order to investigate the potential association between four polymorphisms in the MMP gene and breast cancer risk. A database search yielded a total of 9 studies involving 2,597 cases and 2,618 controls. Four polymorphisms were included in the meta-analysis: MMP-1 −1607 2G/1G (rs1799750), MMP-2 −1306 C/T (rs243865), MMP-3 −1171 6A/5A (rs3025058) and MMP-9 −1562 C/T (rs3918242). Crude odds ratios (OR) with 95% confidence intervals (CI) were used to assess the strength of association. When all the studies were pooled into the meta-analysis, we found that breast cancer cases had a significantly higher frequency of CC genotype (OR = 1.27, 95% CI = 1.10, 1.47; P = 0.001) and lower frequency of CT genotype (OR = 0.78, 95% CI = 0.67, 0.91; P = 0.001) of MMP-2. No significant difference was found in any genotype of MMP-1, MMP-3 or MMP-9. In conclusion, this meta-analysis suggested that MMP-2 −1306 C/T polymorphism may contribute to breast cancer susceptibility. More studies were needed especially in Asians in the future.